An orphan drug 'Jakavi' has got through the barrier of the insurance benefit
‘Jakavi’, which is sincerelywanted by myelofibrosis patients, has finally got throughthe barrier of the insurance benefit evaluation.
Jakavi approved in January 2013was revaluated asa non-insurance benefit product both in June 2013 and January 2014; however, after the third effort on the evaluat...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
